Chonluten
/ Khavinson-tradition tripeptide (Glu-Asp-Gly); proposed chondrogenic / bronchopulmonary bioregulatorALIAS · EDG · Glu-Asp-Gly · Chondrogenic bioregulator
Terms in this page you can click for a plain-English popup: , , , , , , , .
Tier 4. Chonluten (Glu-Asp-Gly) is one of the better-characterised Khavinson-tradition peptides in indexed primary literature, with cell-culture studies of inflammation-pathway and proliferation effects in monocyte/macrophage models. No Phase 1 or later human trials.
Chonluten is a synthetic tripeptide of the Khavinson sequence-specific bioregulator class. In an indexed cell-culture study in the THP-1 human monocytic cell line (Avolio 2022), chonluten was reported alongside epitalon, vilon, thymogen, and thymalin to modulate proliferation-pathway tyrosine phosphorylation and inflammatory-signalling readouts. The proposed tissue targets in the broader Khavinson framework include chondrocyte and bronchopulmonary lineages; molecular target assignment for chonluten specifically has not been definitively established.
Tier 4. The indexed primary evidence is in-vitro cell-culture data on a monocyte/macrophage line (Avolio 2022). No Phase 1 or later human trials of chonluten. Russian-origin gerontology literature includes the compound within broader peptide-bioregulator series.
No formal human safety database. No peptide-specific safety record beyond cell-culture exposure.
Regulatory status
- FDA status:
- Not FDA-approved
Russian-origin literature (Khavinson group, Saint-Petersburg Institute of Bioregulation and Gerontology) without independent Western replication — the Avolio 2022 paper is a Khavinson-collaboration publication (Italian co-authors with Khavinson group) rather than a fully independent replication. The Khavinson tetra/tripeptide tissue-targeting model has not been validated by independent labs. Vendor sales presume tissue-specific regenerative effects that the in-vitro literature alone cannot establish.